Prostate cancer stage describes how far the cancer has spread anatomically—from disease confined to the prostate, through extension into nearby tissues or regional lymph nodes, to cancer that has metastasized to distant parts of the body. The core anatomical system is TNM: T describes the primary prostate tumor, N describes regional pelvic lymph nodes and M describes distant metastasis. In the AJCC stage-group system, TNM is then combined with PSA and Grade Group to assign an overall stage from I through IV. Stage is therefore related to grade, but the two are not interchangeable.
In practical language, localized prostate cancer is contained within the prostate, usually T1–T2 N0 M0; locally advanced disease has grown beyond the prostate into nearby tissues, generally T3–T4 without distant metastasis; regional node-positive disease has reached pelvic lymph nodes, N1 M0; and metastatic prostate cancer is M1 disease involving non-regional lymph nodes, bone or other distant organs. These clinical descriptions are useful, but they do not map perfectly onto every AJCC Roman-numeral stage because PSA and Grade Group also affect stage grouping.
01How Is Prostate Cancer Staged? TNM, PSA, Grade Group and Stage I–IV
TNM describes anatomical extent
The internationally used TNM framework separates the anatomical problem into three questions:
- T — Tumor: how far has the primary prostate tumor extended locally?
- N — Nodes: has cancer reached regional pelvic lymph nodes?
- M — Metastasis: has cancer reached distant lymph nodes, bone or other organs?
Current European Association of Urology guidance strongly recommends TNM classification for prostate-cancer staging.
What does T1 prostate cancer mean?
T1 cancer is clinically inapparent rather than clearly palpable as a prostate mass.
Important subcategories include:
- T1a: cancer is found incidentally in 5% or less of tissue removed during another prostate procedure;
- T1b: incidental cancer occupies more than 5% of that tissue;
- T1c: cancer is found by needle biopsy, commonly during evaluation of an elevated PSA.
Many contemporary screen-detected prostate cancers begin as T1c disease.
What does T2 prostate cancer mean?
T2 means the tumor is clinically confined to the prostate.
Clinical subcategories traditionally include:
- T2a: one half of one prostate lobe or less;
- T2b: more than half of one lobe but not both lobes;
- T2c: both lobes involved.
T1 and T2 are generally the anatomical territory described as localized prostate cancer.
What does T3 mean?
T3 means the cancer has extended beyond a purely organ-confined state.
- T3a: extraprostatic or extracapsular extension.
- T3b: invasion of one or both seminal vesicles.
This is generally considered locally advanced disease.
What does T4 mean?
T4 describes tumor that is fixed or directly invades adjacent structures beyond the seminal vesicles.
Examples can include structures involved in urinary control, the rectum or the pelvic wall.
T4 remains a local-regional anatomical category unless distant metastases are also present.
What do N0 and N1 mean?
The N category concerns regional pelvic lymph nodes.
- N0: no regional lymph-node metastasis identified.
- N1: regional lymph-node metastasis is present.
N1 disease is more advanced than prostate-confined cancer, but it is not the same as distant lymph-node metastasis.
What do M0 and M1 mean?
- M0: no distant metastasis identified.
- M1: distant metastatic disease is present.
M1 is divided further:
- M1a: metastasis to non-regional lymph nodes;
- M1b: bone metastasis;
- M1c: metastasis to another distant site.
What is clinical stage versus pathological stage?
A stage assigned before definitive surgery is generally a clinical stage.
It uses information available before the whole prostate has been examined, including:
- digital rectal examination;
- biopsy pathology;
- PSA;
- and imaging information.
European guidance makes an important technical distinction: formal cT stage is based on clinical examination, while MRI findings such as extraprostatic extension should also be reported separately rather than silently replacing that cT designation.
What does pT mean?
If the prostate is removed surgically, a pathologist can examine the whole surgical specimen and assign a pathological T stage, or pT.
For example:
- pT2: organ-confined prostate cancer;
- pT3a: extraprostatic extension and/or qualifying microscopic bladder-neck invasion;
- pT3b: seminal-vesicle invasion.
Pathological staging can reveal disease that was not fully apparent before surgery.
How are Roman-numeral stages assigned?
The AJCC stage-group system combines:
- T category;
- N category;
- M category;
- PSA at diagnosis;
- Grade Group.
This means an overall stage is not always a simple synonym for anatomical location.
| AJCC stage | Typical defining pattern | Important interpretation |
|---|---|---|
| Stage I | Low-volume T1 or limited T2 disease, N0 M0, Grade Group 1, PSA below 10. | Localized and generally biologically favorable. |
| Stage IIA | Localized Grade Group 1 disease with somewhat greater T extent or PSA 10 to below 20. | Still no nodes or distant metastases. |
| Stage IIB | T1–T2, N0 M0, Grade Group 2, PSA below 20. | Localized disease with pattern 4 present. |
| Stage IIC | T1–T2, N0 M0, Grade Group 3 or 4, PSA below 20. | Can remain anatomically prostate-confined despite higher grade. |
| Stage IIIA | T1–T2, N0 M0, Grade Group 1–4, PSA 20 or higher. | Can still be anatomically confined to the prostate; high PSA drives the stage group. |
| Stage IIIB | T3–T4, N0 M0, Grade Group 1–4. | Local extension beyond the prostate is the defining feature. |
| Stage IIIC | Any T, N0 M0, Grade Group 5. | Very high-grade histology can define stage III even without distant spread. |
| Stage IVA | Any T, N1, M0. | Regional pelvic lymph-node metastasis without distant metastasis. |
| Stage IVB | Any T, any N, M1. | Distant metastatic prostate cancer. |
“Localized, locally advanced and metastatic” are clinically useful anatomical descriptions, but they are not exact substitutes for Stage I, II, III and IV. For example, Stage IIIA can still be T1–T2 and prostate-confined, while Stage IIIC can be assigned because of Grade Group 5 even if N0 M0. Always read the actual T, N, M, PSA and Grade Group rather than relying on the Roman numeral alone.
02What Does Localized Prostate Cancer Mean?
Localized means the cancer remains within the prostate
Anatomically localized prostate cancer generally means:
T1–T2, N0, M0.
There is no identified:
- extension beyond the prostate;
- regional lymph-node metastasis;
- or distant metastatic disease.
Localized does not mean all localized cancers behave the same
A localized tumor can range from:
- a small Grade Group 1 cancer with a low PSA;
- to prostate-confined Grade Group 4 disease;
- or even very high-grade Grade Group 5 disease that has not yet spread anatomically.
That is why clinicians use risk groups in addition to anatomical stage.
What is low-risk localized prostate cancer?
Although exact systems differ, low-risk disease generally combines favorable features such as:
- prostate-confined clinical stage;
- low PSA;
- Grade Group 1;
- and limited tumor burden.
For many appropriately selected men, active surveillance is a standard management option.
Does localized prostate cancer always need immediate treatment?
No.
Immediate treatment may provide little benefit for some slowly growing low-risk cancers while exposing a patient to urinary, sexual or bowel side effects.
Active surveillance may therefore monitor:
- PSA;
- clinical status;
- MRI;
- and repeat tissue assessment when indicated.
What about intermediate-risk localized disease?
Intermediate-risk disease is more heterogeneous.
It can include cancers with:
- Grade Group 2 or 3;
- intermediate PSA values;
- or greater local tumor extent while remaining confined to the prostate.
Current European risk classification further separates favorable from unfavorable intermediate-risk disease because prognosis and staging needs differ within this broad category.
What about high-risk localized disease?
A cancer can be described as high-risk while still having no known distant metastasis.
High risk may reflect:
- high Grade Group;
- high PSA;
- or adverse local tumor characteristics.
This distinction matters because high-risk localized cancer may warrant metastatic staging even though the primary tumor has not produced obvious distant symptoms.
When is additional staging imaging needed?
Current EAU guidance does not recommend additional metastatic staging imaging for low-risk or favorable intermediate-risk localized disease.
For unfavorable intermediate-risk disease, more sensitive staging may be appropriate.
For high-risk localized or locally advanced disease, current EAU guidance recommends metastatic screening using:
- PSMA PET/CT when available;
- or at least cross-sectional abdominopelvic imaging plus a bone scan.
Does localized disease mean cure is guaranteed?
No.
Localized prostate cancer is often highly treatable, but outcome depends on:
- Grade Group;
- PSA;
- tumor volume;
- risk group;
- pathological features;
- and response to treatment or surveillance.
Localized is an anatomical description, not a synonym for low risk. A prostate-confined Grade Group 1 cancer and a prostate-confined Grade Group 5 cancer occupy the same organ but have very different biological risk.
03What Is Locally Advanced Prostate Cancer and How Is Regional Node-Positive Disease Different?
Locally advanced cancer has grown beyond the prostate
The term usually refers to cancer that has extended through the prostate boundary or into nearby structures without confirmed distant metastasis.
Typical TNM categories include:
- T3a extraprostatic extension;
- T3b seminal-vesicle invasion;
- T4 invasion of adjacent structures.
Is locally advanced prostate cancer the same as metastatic cancer?
No.
A locally advanced tumor may still be:
N0 M0.
That means no regional lymph-node metastasis and no distant metastasis have been identified.
Curative-intent treatment can still be appropriate in selected patients.
How does MRI help with local extension?
Prostate MRI can provide information about:
- extraprostatic extension;
- seminal-vesicle invasion;
- relationship to the bladder neck;
- and other nearby pelvic structures.
MRI therefore contributes important anatomical information even though it does not replace pathology for cancer grading.
What is regional node-positive prostate cancer?
Regional lymph-node disease is N1.
These nodes are part of the pelvic lymphatic drainage region.
In the AJCC system:
Any T, N1, M0 = Stage IVA.
Why is N1 not called distant metastasis?
Because TNM separates regional nodes from distant sites.
A pelvic regional node belongs to the N category.
A non-regional lymph node belongs to:
M1a.
How is locally advanced disease usually treated?
Management is frequently multimodal.
Depending on anatomy, Grade Group, PSA, lymph-node status, age, health and patient goals, options can include:
- radiation therapy;
- androgen-deprivation therapy in conjunction with radiation for selected risk groups;
- radical prostatectomy in carefully selected patients as part of a broader treatment strategy;
- and additional systemic treatment in certain high-risk or node-positive settings.
No single treatment is universally preferred for every locally advanced patient.
Does Stage III always mean the cancer has physically grown outside the prostate?
No.
This is a major staging nuance.
AJCC Stage III includes:
- IIIA: T1–T2 disease with PSA 20 or higher;
- IIIB: T3–T4 local extension;
- IIIC: Grade Group 5 disease with N0 M0, regardless of T category.
Only IIIB specifically requires T3–T4 local extension.
Can locally advanced disease still be treated with curative intent?
Yes, in selected patients.
Locally advanced means anatomically more extensive than organ-confined disease; it does not mean local cure is automatically impossible.
Treatment decisions depend heavily on:
- exact T category;
- nodal status;
- Grade Group;
- PSA;
- overall health;
- and expected benefit from combined treatment.
Local extension, regional nodal spread and distant metastasis should be kept separate. A T3b N0 M0 cancer, a T2 N1 M0 cancer and a T2 N0 M1b cancer are three different anatomical disease states even if the biopsy Grade Group is identical.
04What Is Metastatic Prostate Cancer and How Does Stage IV Change Management?
Metastatic prostate cancer means M1 disease
Metastatic prostate cancer has spread beyond the regional pelvic area to a distant site.
TNM divides this into:
- M1a: non-regional lymph nodes;
- M1b: bone;
- M1c: another distant organ or site.
Where does prostate cancer commonly metastasize?
Bone is a common metastatic site.
Frequently involved skeletal locations include:
- spine;
- pelvis;
- ribs;
- and other axial skeletal sites.
Prostate cancer can also spread to distant lymph nodes and visceral organs.
Is all Stage IV prostate cancer metastatic?
No.
This is another important distinction.
- Stage IVA: N1 M0 — regional lymph-node disease without distant metastasis.
- Stage IVB: M1 — distant metastatic disease.
Therefore the phrase “stage 4” should ideally be clarified as IVA or IVB.
How is metastatic disease detected?
Staging may use:
- PSMA PET/CT;
- CT or MRI;
- bone scan;
- and other imaging selected for the clinical situation.
Current EAU guidance notes that PSMA PET/CT and whole-body MRI are more sensitive for lymph-node and bone metastases than older conventional staging with CT and bone scan.
Does more sensitive imaging create staging challenges?
Yes.
Modern PSMA PET can identify very small sites of disease that conventional imaging would previously have missed.
That creates a phenomenon known as stage migration: patients who once would have been classified as nonmetastatic may now be placed into a metastatic imaging category.
Current European guidance cautions that the ideal management of every patient whose metastases are detected only by highly sensitive modern imaging is still evolving.
What is metastatic hormone-sensitive prostate cancer?
A patient can have M1 metastatic disease while the cancer still responds to androgen suppression.
This is commonly called:
metastatic hormone-sensitive prostate cancer
or:
metastatic castration-sensitive prostate cancer.
This is a treatment-response state, not a new TNM stage.
What is metastatic castration-resistant prostate cancer?
Castration-resistant disease means the cancer progresses despite testosterone being suppressed to a castrate level.
A patient can therefore move biologically from:
metastatic hormone-sensitive → metastatic castration-resistant
without changing the original fact that the anatomical disease is M1.
How does metastatic status change treatment?
Once distant metastasis is established, systemic treatment becomes central.
For metastatic hormone-sensitive disease, modern treatment usually does not rely on androgen-deprivation therapy alone when the patient is suitable for treatment intensification.
Approaches can include:
- androgen-deprivation therapy;
- androgen-receptor pathway inhibitors;
- chemotherapy in selected patients;
- or combinations of systemic treatments.
Radiation to the prostate or metastatic sites can also have a role in selected settings.
Treatment depends on:
- volume and distribution of metastatic disease;
- symptoms;
- prior treatment;
- genomic findings;
- fitness and comorbidities;
- and whether the disease remains hormone-sensitive.
Does metastatic prostate cancer always cause symptoms?
No.
Some metastases are found on staging imaging before symptoms appear.
When symptoms do occur, they can include:
- persistent focal bone pain;
- fatigue;
- weight loss;
- anemia-related symptoms;
- or symptoms related to the specific metastatic site.
What symptoms can suggest spinal cord compression?
Cancer involving the spine can rarely compress the spinal cord or cauda equina.
Urgent medical assessment is needed for new or rapidly worsening back pain accompanied by leg weakness, numbness, difficulty walking, saddle-area sensory loss or new loss of bladder or bowel control. These symptoms can indicate spinal cord or cauda-equina compression. Back pain alone is common and does not by itself mean metastatic prostate cancer.
Does bone metastasis mean every bone hurts?
No.
Bone metastases can be:
- asymptomatic;
- focally painful;
- or detected only by imaging.
The presence and severity of pain do not precisely measure metastatic burden.
Can metastatic prostate cancer still respond well to treatment?
Yes.
Metastatic prostate cancer is generally considered a systemic disease rather than a condition cured by treatment to the prostate alone, but modern systemic therapy can substantially control disease in many patients.
Response and duration vary widely according to:
- tumor biology;
- disease volume;
- sites of metastasis;
- genomic alterations;
- and treatment response.
Do not confuse “metastatic,” “advanced,” “castration-resistant” and “recurrent.” Metastatic describes anatomical spread. Castration-resistant describes progression despite androgen suppression. Recurrent describes cancer returning after prior treatment. These concepts can overlap, but they are not synonyms.
→Localized, Locally Advanced, Regional and Metastatic Prostate Cancer Compared
| Disease state | Typical TNM pattern | Where cancer is located | General management context |
|---|---|---|---|
| Localized | T1–T2 N0 M0 | Within the prostate. | Risk-adapted approach ranging from active surveillance to surgery or radiation. |
| Locally advanced | Generally T3–T4 N0 M0 | Beyond the prostate into nearby tissues or seminal vesicles, without distant metastasis. | Often multimodal; radiation plus systemic therapy or surgery in selected patients can be considered. |
| Regional node-positive | Any T N1 M0 | Regional pelvic lymph nodes involved. | AJCC Stage IVA; management commonly combines local and systemic considerations. |
| Distant nodal metastatic | M1a | Non-regional lymph nodes. | Systemic metastatic-disease treatment framework. |
| Bone metastatic | M1b | One or more bone sites. | Systemic therapy; bone-directed symptom management when needed. |
| Other distant metastatic | M1c | Distant organ or other non-bone site. | Systemic metastatic-disease framework with treatment individualized to site and biology. |
?Common Questions About Prostate Cancer Stages
| Question | Practical answer |
|---|---|
| What does prostate cancer stage mean? | Stage describes the anatomical extent of cancer—whether it is confined to the prostate, has reached nearby tissues or nodes, or has metastasized to distant sites. |
| What does TNM stand for? | Tumor, Nodes and Metastasis. |
| What is T1 prostate cancer? | Clinically inapparent cancer that is not clearly palpable as a prostate tumor. |
| What is T1c? | Cancer identified by needle biopsy, commonly during investigation of an elevated PSA. |
| What is T2? | Cancer that remains anatomically confined within the prostate. |
| What is T3a? | Extraprostatic extension beyond the prostate boundary. |
| What is T3b? | Seminal-vesicle invasion. |
| What is T4? | Direct invasion into adjacent structures beyond the seminal vesicles or a fixed tumor. |
| What does N0 mean? | No regional lymph-node metastasis has been identified. |
| What does N1 mean? | Prostate cancer is present in regional pelvic lymph nodes. |
| Does N1 mean metastatic Stage IVB disease? | No. N1 M0 is AJCC Stage IVA. Distant metastatic Stage IVB requires M1 disease. |
| What does M0 mean? | No distant metastatic disease has been identified. |
| What does M1 mean? | Distant metastasis is present. |
| What is M1a? | Metastasis to non-regional lymph nodes. |
| What is M1b? | Bone metastasis. |
| What is M1c? | Metastasis to another distant site or organ. |
| What is localized prostate cancer? | Cancer confined to the prostate, generally T1–T2 N0 M0. |
| Is all localized prostate cancer low risk? | No. Grade Group and PSA can make an anatomically localized tumor intermediate- or high-risk. |
| What is locally advanced prostate cancer? | Cancer that has grown beyond the prostate into nearby tissues, commonly T3 or T4, without distant metastasis. |
| Is locally advanced the same as metastatic? | No. T3–T4 N0 M0 disease is locally advanced but not metastatic. |
| What is Stage III prostate cancer? | A heterogeneous AJCC group that can be defined by PSA 20 or higher, T3–T4 local extension, or Grade Group 5 while remaining N0 M0. |
| Does Stage III always mean the tumor has left the prostate? | No. Stage IIIA can still be T1–T2, and Stage IIIC can be assigned because of Grade Group 5. |
| What is Stage IVA? | Any T, N1, M0: regional pelvic lymph-node metastasis without distant spread. |
| What is Stage IVB? | M1 disease: distant metastatic prostate cancer. |
| Is Grade Group 4 the same as Stage IV? | No. Grade Group describes microscopic aggressiveness; Stage IV describes anatomical disease extent. |
| Is Grade Group 5 the same as Stage V? | No. Conventional prostate-cancer stages run from I through IV. Grade Group 5 is a pathology category, not “Stage V.” |
| Can Stage IV prostate cancer have no distant metastases? | Yes. Stage IVA is N1 M0 regional node-positive disease. |
| Can high-grade prostate cancer still be localized? | Yes. Grade Group 4 or 5 can be diagnosed before any regional or distant spread is identified. |
| Does PSA determine stage? | PSA contributes to AJCC stage grouping and clinical risk classification, but it does not by itself define anatomical T, N or M extent. |
| Does Gleason score determine stage? | Grade Group contributes to overall AJCC stage grouping but remains distinct from anatomical TNM stage. |
| Does MRI determine the Gleason score? | No. MRI shows anatomy and lesion characteristics; pathology determines Gleason patterns and Grade Group. |
| Can MRI show cancer outside the prostate? | Yes. MRI can provide evidence of extraprostatic extension and seminal-vesicle invasion. |
| When is PSMA PET/CT used? | It is increasingly used for staging selected unfavorable intermediate-risk, high-risk, locally advanced, recurrent or metastatic clinical settings rather than routine staging of every low-risk patient. |
| What is pathological stage? | Stage assigned from tissue removed during surgery, allowing direct examination of the prostate and surrounding sampled structures. |
| Can pathological stage differ from clinical stage? | Yes. Surgery may reveal extension or other findings that were not identified before treatment. |
| Does metastatic prostate cancer always cause bone pain? | No. Some metastatic disease is asymptomatic and detected only on imaging. |
| What symptoms require urgent assessment in a patient with spinal metastases? | New worsening back pain with leg weakness, numbness, walking difficulty or new bladder/bowel dysfunction can indicate spinal cord or cauda-equina compression. |
| Is metastatic hormone-sensitive disease a stage? | No. It is a biological treatment-response state within metastatic disease. |
| Is castration-resistant prostate cancer a new TNM stage? | No. It describes progression despite adequate androgen suppression. |
ΣKey Clinical Takeaways
- Prostate cancer stage describes anatomical disease extent.
- Grade describes microscopic aggressiveness.
- Risk group combines stage, PSA, Grade Group and other clinical factors.
- TNM is the core anatomical staging framework.
- T describes the primary prostate tumor.
- N describes regional pelvic lymph nodes.
- M describes distant metastasis.
- T1 cancer is clinically inapparent.
- T1c commonly refers to cancer diagnosed by needle biopsy after PSA-based investigation.
- T2 cancer is confined to the prostate.
- T3a means extraprostatic extension.
- T3b means seminal-vesicle invasion.
- T4 means direct extension into adjacent structures beyond the seminal vesicles or fixation.
- N0 means no regional nodal metastasis is identified.
- N1 means regional pelvic lymph-node metastasis.
- N1 is not the same as distant nodal metastasis.
- M0 means no distant metastatic disease is identified.
- M1 means distant metastatic disease is present.
- M1a means non-regional lymph-node metastasis.
- M1b means bone metastasis.
- M1c means another distant metastatic site.
- Localized prostate cancer is generally T1–T2 N0 M0.
- Localized does not automatically mean low-risk.
- A high-grade cancer can still be anatomically localized.
- Locally advanced prostate cancer generally includes T3–T4 disease without distant metastasis.
- Locally advanced does not automatically mean incurable or metastatic.
- Selected locally advanced cancers can still be treated with curative intent.
- Regional node-positive N1 M0 disease is AJCC Stage IVA.
- Distant M1 disease is AJCC Stage IVB.
- Stage III is not synonymous with local extension.
- Stage IIIA can be T1–T2 disease driven by PSA 20 or higher.
- Stage IIIB represents T3–T4 local extension in the relevant AJCC grouping.
- Stage IIIC can be assigned because of Grade Group 5 despite N0 M0.
- AJCC overall stage combines TNM with PSA and Grade Group.
- Clinical stage and pathological stage can differ.
- Current EAU guidance recommends formal TNM staging.
- EAU clinical cT stage is based on clinical examination, with MRI findings reported additionally.
- MRI can provide important local-staging information.
- Low-risk and favorable intermediate-risk localized disease generally do not require routine additional metastatic staging imaging.
- High-risk localized and locally advanced disease generally require metastatic staging.
- PSMA PET/CT is more sensitive than older conventional imaging for many nodal and bone metastases.
- More sensitive imaging can cause stage migration.
- Metastatic prostate cancer commonly involves bone.
- Bone metastasis is M1b.
- Metastatic disease can be asymptomatic.
- Spinal cord compression is an emergency when neurological red flags accompany new or worsening back pain.
- Metastatic hormone-sensitive prostate cancer and metastatic castration-resistant prostate cancer are treatment-response states, not different TNM stages.
- No prostate-cancer stage by itself determines one universally preferred treatment.
- Management must integrate stage, Grade Group, PSA, cancer burden, health, life expectancy, urinary/bowel/sexual function and patient priorities.
Clinical bottom line: prostate cancer staging is a map of anatomical disease extent. TNM asks whether cancer remains in the prostate, has crossed into nearby structures, has reached regional pelvic lymph nodes or has metastasized to distant sites. Localized disease is usually T1–T2 N0 M0; locally advanced disease generally reflects T3–T4 extension; N1 identifies regional node-positive cancer; and M1 identifies distant metastatic disease. Overall AJCC stages I through IV also incorporate PSA and Grade Group, so Roman numerals should not be treated as simple synonyms for localized, locally advanced or metastatic disease. The most useful staging interpretation therefore reads T, N, M, PSA and Grade Group together before prognosis or treatment is discussed.
Medical disclaimer: This article provides general medical education about prostate-cancer staging. An individual’s stage and treatment options depend on pathology, PSA, Grade Group, clinical examination, MRI, lymph-node and metastatic imaging when indicated, overall health and previous treatment. Staging systems and imaging interpretation should be reviewed with the treating urology or oncology team.
For the pathology grade that complements stage, review What Is the Gleason Score? and Gleason Score vs Grade Group. For the sequence that establishes a tissue diagnosis before staging, see How Prostate Cancer Is Diagnosed, Prostate MRI, Prostate Biopsy and MRI-Targeted Prostate Biopsy. For the blood marker that contributes to risk and AJCC stage grouping, see PSA Testing. For the complete disease framework, return to the Prostate Cancer hub. The next guide explains localized prostate cancer—what it means when cancer remains in the prostate, how localized disease is divided by risk and when surveillance, surgery or radiation may be considered.
Evidence Sources
- European Association of Urology — Prostate Cancer Classification and Staging Systems: TNM definitions, clinical and pathological staging, regional and distant metastatic categories, Grade Group and risk classification.
- European Association of Urology — Diagnostic Evaluation: MRI for local staging, PSMA PET/CT, bone and lymph-node staging, and current recommendations for low-, intermediate- and high-risk disease.
- European Association of Urology — Prostate Cancer Treatment: stage- and risk-adapted management of localized, locally advanced, node-positive and metastatic prostate cancer.
- EAU Patient Information — Localised Prostate Cancer: patient-facing definition and treatment context for cancer contained within the prostate.
- EAU Patient Information — Locally Advanced Prostate Cancer: disease extending beyond the prostate and available management approaches.
- EAU Patient Information — Advanced Metastatic Prostate Cancer: distant spread and systemic-treatment context.
- American Cancer Society — Prostate Cancer Stages: AJCC TNM stage grouping, PSA, Grade Group, Stages I through IV and IVA versus IVB.
- National Cancer Institute — Prostate Cancer Treatment PDQ, Health Professional Version: stage-specific disease definitions, prognosis and treatment context.
- National Cancer Institute — Hormone Therapy for Prostate Cancer: metastatic hormone-sensitive disease, treatment intensification and castration-resistant disease context.
